PCSA insider trading
NasdaqCM HealthcareProcessa Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
Company website: www.processapharmaceuticals.com
PCSA insider activity at a glance
FilingIQ has scored 200 insider transactions for PCSA since Oct 1, 2020. The most recent filing in our index is dated Apr 30, 2026.
Across the full history, 54 open-market purchases
and 17 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on PCSA insider trades is 64.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest PCSA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading PCSA
Frequently asked
- How many insider trades does FilingIQ track for PCSA?
- FilingIQ tracks 200 Form 4 insider transactions for PCSA (Processa Pharmaceuticals, Inc.), covering filings from Oct 1, 2020 onwards. 23 of those were filed in the last 90 days.
- Are PCSA insiders net buyers or net sellers?
- Across the full Form 4 history for PCSA, 54 transactions (27%) were open-market purchases and 17 (9%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does PCSA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is PCSA in?
- Processa Pharmaceuticals, Inc. (PCSA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $6.78M.
Methodology & sources
Every PCSA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.